Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in Sudan to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been developing in the country due to various factors.
Customer preferences: Patients in Sudan prefer using bronchodilator drugs that have a fast onset of action and a long duration of effect. They also prefer drugs that are affordable and easily accessible. As a result, generic drugs are more popular than branded ones.
Trends in the market: The bronchodilator drugs market in Sudan has been growing steadily due to an increase in the prevalence of respiratory diseases. The market has also been driven by the availability of low-cost generic drugs. In recent years, there has been a shift towards combination therapies, which offer better efficacy and convenience for patients. This trend is expected to continue in the future.
Local special circumstances: Sudan is a low-income country with a large population that is predominantly rural. The healthcare system is underdeveloped, and access to healthcare is limited in many parts of the country. This has led to a high burden of respiratory diseases, which has in turn driven the demand for bronchodilator drugs. The government has been working to improve healthcare infrastructure and increase access to essential medicines, which is expected to further boost the market for bronchodilator drugs.
Underlying macroeconomic factors: Sudan has been facing economic challenges in recent years, including high inflation and a shortage of foreign currency. This has led to an increase in the cost of imported medicines, including bronchodilator drugs. However, the government has taken steps to address these challenges, including implementing economic reforms and seeking support from international donors. These efforts are expected to stabilize the economy and improve access to essential medicines in the long term.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
